Japan Pharmaceuticals and Healthcare Report Q2 208 : Market Research Report

Japan Pharmaceuticals and Healthcare Report Q2 208

Published by: Business Monitor International

Published: Apr. 22, 2008 - 86 Pages

Executive Summary: Japan Pharmaceuticals And Healthcare Industry SWOT; Japan Political SWOT; Japan Economic SWOT; Pharmaceutical Business Environment Ratings; Table: Asia Pacific Pharmaceutical Business Environment Rankings, Q208; Limits Of Potential Returns; Risks To Realisation Of Returns; Japan - Market Summa10; Regulatory Regime; Case Study: Wyeth’s Prevnar and Japanese Drug Lag; Recent Regulatory Developments; Medical Device Regulations; Intellectual Property Developments; Pricing And Reimbursement System; Table: Reimbursement Categories And Rates; Recent Pricing And Reimbursement Developments; Other Regulatory Issues; Table: Concerns Of Pharmaceutical Associations; Industry Trends And Developments; Epidemiology; Table: Mortality By Cause In Japan; Healthcare Sector; Healthcare Sector Finance Issues; Healthcare Reforms; International Collaboration; International Reaction; Domestic Company Activity; Foreign Generic Sector; Table: Timeline: Indian Manufacturers In Japan, 2005-2007; Multinational Sector Developments; Research And Development; Industry Forecast Sce31; Overall Market Forecast; Table: Japanese Ethical Market - Leading Therapeutic Classes, FY05/06; Table: Japan’s Drug Market Indicators; Key Growth Factors - Industry; Table: Japan’s Healthcare Expenditure Indicators; Macroeconomic Forecast Scenario; Table: Japan - Macroeconomic Forecasts; Prescription Market Forecast; Table: Prescription Drug Market Indicators (US$mn unless otherwise stated); OTC Market Forecast; Table: OTC Market Indicators (US$mn unless otherwise stated); Generics Market Forecast; Table: Generics Market Trends; Patented Medicines Market Forecast; Table: Patented Medicines Market Indicators; Export/Import Forecasts; Table: Export/Import Trends (US$mn); Other Healthcare Data And Forecasts; Table: Socio-Demographic Indicators; Key Risks To BMI’s Forecast Scenario; Competitive Landscape.51; Table: Japanese Ethical Market - Sales Value (FY2006); Company Profiles; Leading Foreign Manufacturers; Pfizer; Sanofi-Aventis; Merck & Co (Banyu); Novartis; GlaxoSmithKline (GSK); AstraZeneca; Indigenous Manufacturers; Takeda; Astellas; Eisai; Daiichi-Sankyo; Sawai Pharmaceutical; BMI Forecast Modelling; How We Generate Our Industry Forecasts; Pharmaceutical Industry; Pharmaceutical Business Environment Ratings Methodology; Ratings Overview; Table: Pharmaceutical Business Environment Indicators; Weighting; Table: Weighting Of Components; Sources

Abstract

Japan’s pharmaceutical market is currently valued at US$74.4bn and is easily the most mature in the Asia
Pacific region. Top-line sales stagnated for the first time in 2006 and this scenario is likely to be repeated
in 2007. However, this is a temporary trend as the country’s vast ageing population will cause the market
to expand once again. By 2012, we expect the value of market to reach US$82.0bn.

The country’s generics sector is one of the most promising in BMI’s coverage universe. In an effort to
control ballooning healthcare costs, the ministry of health plans to raise the volumes share of generics
within the total prescription market to at least 30% by 2012. The current value of the sector is US$5.5bn,
which equates to 7.3% of total medicines sales. Changes to prescribing procedures and the influx of
foreign firms with low-cost goods will provide a stimulus to the generic drug sector.

It has emerged that the debilitating and sometime deadly viral condition hepatitis C is grossly underdiagnosed
in Japan. Spurred on by a tainted blood scandal, the government is looking to increase
awareness of the disease, which is estimated to affect 1.4% of the population, or 1.75mn people. BMI
believes that this campaign will provide a boost for manufacturers of testing kits and pharmaceutical
companies that sell hepatitis C therapeutics, such as Switzerland's Roche and US firm Schering-Plough.
For fiscal-year 2008, the budget for the Ministry of Health, Labour and Welfare (MHLW) was been
increased by 3.0% to JPY222bn (US$221bn). This compares favourably to overall economic growth in
2007, which was estimated to be 2.6% by BMI's Country Risk team. Within the MHLW's spending plan,
emphasis has been placed on cancer prevention, medical research and development (R&D), hepatitis
countermeasures, and stem cell research. Worryingly for drugmakers, funding for accelerated access to
pharmaceuticals has been cut.

During Q108, Novartis became the latest multinational to scale back its research operations in Japan, with
the planned closure of a facility in Tsukuba near Tokyo by the end of 2008. In recent years, numerous
international drugmakers - Pfizer, Schering AG and GlaxoSmithKline (GSK) - have reduced their
R&D footprint in Japan.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Japan Pharmaceuticals and Healthcare Report Q2 208

Table of Contents

Abstract